Clinical Trials in Philadelphia

Showing 4641-4660 of 20,904 trials

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

NCT02052739

The purpose of this study is to evaluate the safety and tolerability of SAGE-547 in participants in super-refractory status epilepticus (SRSE).

Super-refractory Status Epilepticus

Supernus Pharmaceuticals, Inc.25 participantsStarted Mar 2014

Birmingham, Alabama, United States • Sarasota, Florida, United States • Chicago, Illinois, United States +14 more locations

Active Not RecruitingPhase 2/3< 1 mile

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

NCT05397665

This study is designed to assess the efficacy and safety of AT-007 treatment in patients with SORD Deficiency. This randomized, double-blind study will assess the effect of AT-007 compared to Placebo in SORD Deficiency in patients for up to 24 months.

Hereditary Neuropathy Caused by SORD Deficiency

Applied Therapeutics, Inc.56 participantsStarted Jan 2022

Aurora, Colorado, United States • Coral Gables, Florida, United States • Iowa City, Iowa, United States +7 more locations

Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency

Find Trials by Condition in Philadelphia

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease

A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Group Preconception Care for Fertility Patients

Transcranial Magnetic Stimulation and Constraint Induced Language Therapy for Alzheimer Disease

Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures

Cross-Seal Closure Device IDE Trial - Study of the Cross-SealTM Suture-Mediated Vascular Closure Device System

Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex

Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children

Biofeedback Based Virtual Reality Intervention to Manage Postoperative Pain

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

DFC 004 Biomarkers for Active Diabetic Foot Ulcers

A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis